Gösterilen 1 - 5 sonuçlar arası kayıtlar. 5 sonuç. Aranan kelime 'Seyed Reza Mousavi (13223324)', Sorgu süresi: 0.01s Sonuçları Daraltın
  1. 1
    The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.

    The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites. Yazar: Seyed Reza Mousavi (13223324)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  2. 2
    Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].

    Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58]. Yazar: Seyed Reza Mousavi (13223324)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  3. 3
    Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.

    Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites. Yazar: Seyed Reza Mousavi (13223324)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  4. 4
    Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.

    Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites. Yazar: Seyed Reza Mousavi (13223324)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  5. 5
    Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.

    Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites. Yazar: Seyed Reza Mousavi (13223324)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:

Arama Araçları: